Rubius Therapeutics Company

Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics.
Technology: Atrificial Vectors and Immune Cells, Cell-based gene therapy
Industry: Atrificial Vectors and Immune Cells, Public
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2013-01-01
Employees Number: 101-250
Funding Status: IPO
Investors Number: 1
Total Funding: 445000000
Estimated Revenue: $10M to $50M
Last Funding Date: 2021-03-16
Last Funding Type: Post-IPO Equity

Visit Website
info@rubiustx.com
https://twitter.com/rubius_tx
Register and Claim Ownership